Sánchez-Camacho Jennifer Viridiana, Gómez-Chavarín Margarita, Galindo-Solano Nuria, Padilla-Cortés Patricia, Maldonado-García José Luis, Pérez-Sánchez Gilberto, Pavón Lenin, Ramírez-Santos Jesús, Roldán Roldán Gabriel, Gómez-López Modesto, Gutierrez-Ospina Gabriel
Sección de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
Laboratorio de Medicina Regenerativa y Canales Iónicos, Departamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.
Int J Mol Sci. 2024 Nov 25;25(23):12635. doi: 10.3390/ijms252312635.
The pursuit of nutraceuticals to improve the quality of life for patients with neurodegenerative conditions is a dynamic field within neuropharmacology. Unfortunately, many nutraceuticals that show promise in preclinical studies fail to demonstrate significant clinical benefits in human trials, leading to their exclusion as therapeutic options. This discrepancy may stem from the categorical interpretation of preclinical and clinical results. Basic researchers often assume that non-human experimental animals exhibit less phenotypic variability than humans. This belief overlooks interindividual phenotype variation, thereby leading to categorical conclusions being drawn from experiments. Consequently, when human clinical trials are conducted, the researchers expect similarly conclusive results. If these results are not achieved, the nutraceutical is deemed ineffective for clinical use, even if numerous individuals might benefit. In our study, we evaluated whether analyzing phenotype variability and similarity through non-categorical methods could help identify rotenone (ROT)-treated rats that might benefit from consuming nano-emulsified punicic acid (Nano-PSO), even if the prevention of "parkinsonism" or the restoration of neurometabolic function is inconsistent across individuals. Our findings supported this hypothesis. The benefits of Nano-PSO were not categorical; however, analyzing phenotype variance allowed us to identify ROT rats with varying degrees of benefit from Nano-PSO consumption. Hence, the translational potential of results from basic science studies testing nutraceuticals as pharmaceutical products against neurodegeneration may improve if researchers also interpret their results using non-categorical methods of data analysis for population screening, even if the overall therapeutic outcomes for the entire population show internal inconsistencies.
寻求营养保健品以改善神经退行性疾病患者的生活质量是神经药理学领域内一个充满活力的研究方向。不幸的是,许多在临床前研究中显示出前景的营养保健品在人体试验中未能证明具有显著的临床益处,导致它们被排除在治疗选择之外。这种差异可能源于对临床前和临床结果的分类解释。基础研究人员通常认为非人类实验动物表现出的表型变异性比人类小。这种观点忽视了个体间的表型变异,从而导致从实验中得出分类结论。因此,在进行人体临床试验时,研究人员期望得到同样确凿的结果。如果没有达到这些结果,即使许多个体可能会从中受益,该营养保健品也会被认为对临床使用无效。在我们的研究中,我们评估了通过非分类方法分析表型变异性和相似性是否有助于识别即使在预防“帕金森症”或恢复神经代谢功能方面个体间存在不一致,但仍可能从食用纳米乳化石榴酸(Nano-PSO)中受益的鱼藤酮(ROT)处理大鼠。我们的研究结果支持了这一假设。Nano-PSO的益处并非绝对;然而,分析表型差异使我们能够识别出从食用Nano-PSO中获得不同程度益处的ROT大鼠。因此,如果研究人员在进行针对神经退行性疾病的营养保健品基础科学研究时,也使用非分类数据分析方法进行人群筛选来解释其结果,那么将营养保健品作为药物产品进行测试的基础科学研究结果的转化潜力可能会提高,即使整个人群的总体治疗结果显示出内部不一致性。